Immunogenicity of SARS inactivated vaccine in BALB/c mice.
Identifieur interne : 002B45 ( PubMed/Corpus ); précédent : 002B44; suivant : 002B46Immunogenicity of SARS inactivated vaccine in BALB/c mice.
Auteurs : Sheng Xiong ; Yi-Fei Wang ; Mei-Ying Zhang ; Xin-Jian Liu ; Chuan-Hai Zhang ; Shi-Sheng Liu ; Chui-Wen Qian ; Jiu-Xiang Li ; Jia-Hai Lu ; Zhuo-Yue Wan ; Huan-Yin Zheng ; Xin-Ge Yan ; Min-Jie Meng ; Jiang-Lin FanSource :
- Immunology letters [ 0165-2478 ] ; 2004.
English descriptors
- KwdEn :
- Animals, Antibodies, Viral (blood), Antibodies, Viral (immunology), Antibody Specificity, Antigens, Viral (immunology), Immune Sera (immunology), Immunoglobulin G (blood), Immunoglobulin G (immunology), Kinetics, Mice, Mice, Inbred BALB C, Neutralization Tests, SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (virology), Vaccines, Inactivated (immunology), Viral Vaccines (immunology).
- MESH :
- chemical , blood : Antibodies, Viral, Immunoglobulin G.
- chemical , immunology : Antibodies, Viral, Antigens, Viral, Immune Sera, Immunoglobulin G, Vaccines, Inactivated, Viral Vaccines.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- virology : Severe Acute Respiratory Syndrome.
- Animals, Antibody Specificity, Kinetics, Mice, Mice, Inbred BALB C, Neutralization Tests.
Abstract
Severe acute respiratory syndrome (SARS) is a serious infectious threat to public health. To create a novel trial vaccine and evaluate its potency, we attempted to generate a SARS inactivated vaccine using SARS coronavirus (SARS-CoV) strain F69 treated with formaldehyde and mixed with Al(OH)3. Three doses of the vaccine were used to challenge three groups of BALB/c mice. We found that the mice exhibited specific IgM on day 4 and IgG on day 8. The peak titers of IgG were at day 47 in low-dose group (1:19,200) and high-dose group (1:38,400) whereas in middle-dose group (1:19,200), the peak was at day 40. On day 63, the IgG levels reached a plateau. Neutralization assay demonstrated that the antisera could protect Vero-E6 cells from SARS-CoV's infection. Analysis of the antibody specificity revealed that the mouse antisera contained a mixture of antibodies specifically against the structure proteins of SARS-CoV. Furthermore, the mouse antisera conferred higher amount of antibodies against protein N, polypeptide S4 and S2 than those of proteins M and 3CL. These findings suggest that the inactivated SARS-CoV could preserve its antigenicity and the inactivated vaccine can stimulate mice to produce high levels of antibodies with neutralization activity. Results also suggest that polypeptides originating from protein N or S might be a potential target for the generation of a recombinant SARS vaccine.
DOI: 10.1016/j.imlet.2004.06.014
PubMed: 15388253
Links to Exploration step
pubmed:15388253Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immunogenicity of SARS inactivated vaccine in BALB/c mice.</title>
<author><name sortKey="Xiong, Sheng" sort="Xiong, Sheng" uniqKey="Xiong S" first="Sheng" last="Xiong">Sheng Xiong</name>
<affiliation><nlm:affiliation>Biomedical Research & Development Center, Floor 5, Building of Biology, Jinan University, Guangzhou 510630, PR China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Wang, Yi Fei" sort="Wang, Yi Fei" uniqKey="Wang Y" first="Yi-Fei" last="Wang">Yi-Fei Wang</name>
</author>
<author><name sortKey="Zhang, Mei Ying" sort="Zhang, Mei Ying" uniqKey="Zhang M" first="Mei-Ying" last="Zhang">Mei-Ying Zhang</name>
</author>
<author><name sortKey="Liu, Xin Jian" sort="Liu, Xin Jian" uniqKey="Liu X" first="Xin-Jian" last="Liu">Xin-Jian Liu</name>
</author>
<author><name sortKey="Zhang, Chuan Hai" sort="Zhang, Chuan Hai" uniqKey="Zhang C" first="Chuan-Hai" last="Zhang">Chuan-Hai Zhang</name>
</author>
<author><name sortKey="Liu, Shi Sheng" sort="Liu, Shi Sheng" uniqKey="Liu S" first="Shi-Sheng" last="Liu">Shi-Sheng Liu</name>
</author>
<author><name sortKey="Qian, Chui Wen" sort="Qian, Chui Wen" uniqKey="Qian C" first="Chui-Wen" last="Qian">Chui-Wen Qian</name>
</author>
<author><name sortKey="Li, Jiu Xiang" sort="Li, Jiu Xiang" uniqKey="Li J" first="Jiu-Xiang" last="Li">Jiu-Xiang Li</name>
</author>
<author><name sortKey="Lu, Jia Hai" sort="Lu, Jia Hai" uniqKey="Lu J" first="Jia-Hai" last="Lu">Jia-Hai Lu</name>
</author>
<author><name sortKey="Wan, Zhuo Yue" sort="Wan, Zhuo Yue" uniqKey="Wan Z" first="Zhuo-Yue" last="Wan">Zhuo-Yue Wan</name>
</author>
<author><name sortKey="Zheng, Huan Yin" sort="Zheng, Huan Yin" uniqKey="Zheng H" first="Huan-Yin" last="Zheng">Huan-Yin Zheng</name>
</author>
<author><name sortKey="Yan, Xin Ge" sort="Yan, Xin Ge" uniqKey="Yan X" first="Xin-Ge" last="Yan">Xin-Ge Yan</name>
</author>
<author><name sortKey="Meng, Min Jie" sort="Meng, Min Jie" uniqKey="Meng M" first="Min-Jie" last="Meng">Min-Jie Meng</name>
</author>
<author><name sortKey="Fan, Jiang Lin" sort="Fan, Jiang Lin" uniqKey="Fan J" first="Jiang-Lin" last="Fan">Jiang-Lin Fan</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2004">2004</date>
<idno type="RBID">pubmed:15388253</idno>
<idno type="pmid">15388253</idno>
<idno type="doi">10.1016/j.imlet.2004.06.014</idno>
<idno type="wicri:Area/PubMed/Corpus">002B45</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002B45</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Immunogenicity of SARS inactivated vaccine in BALB/c mice.</title>
<author><name sortKey="Xiong, Sheng" sort="Xiong, Sheng" uniqKey="Xiong S" first="Sheng" last="Xiong">Sheng Xiong</name>
<affiliation><nlm:affiliation>Biomedical Research & Development Center, Floor 5, Building of Biology, Jinan University, Guangzhou 510630, PR China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Wang, Yi Fei" sort="Wang, Yi Fei" uniqKey="Wang Y" first="Yi-Fei" last="Wang">Yi-Fei Wang</name>
</author>
<author><name sortKey="Zhang, Mei Ying" sort="Zhang, Mei Ying" uniqKey="Zhang M" first="Mei-Ying" last="Zhang">Mei-Ying Zhang</name>
</author>
<author><name sortKey="Liu, Xin Jian" sort="Liu, Xin Jian" uniqKey="Liu X" first="Xin-Jian" last="Liu">Xin-Jian Liu</name>
</author>
<author><name sortKey="Zhang, Chuan Hai" sort="Zhang, Chuan Hai" uniqKey="Zhang C" first="Chuan-Hai" last="Zhang">Chuan-Hai Zhang</name>
</author>
<author><name sortKey="Liu, Shi Sheng" sort="Liu, Shi Sheng" uniqKey="Liu S" first="Shi-Sheng" last="Liu">Shi-Sheng Liu</name>
</author>
<author><name sortKey="Qian, Chui Wen" sort="Qian, Chui Wen" uniqKey="Qian C" first="Chui-Wen" last="Qian">Chui-Wen Qian</name>
</author>
<author><name sortKey="Li, Jiu Xiang" sort="Li, Jiu Xiang" uniqKey="Li J" first="Jiu-Xiang" last="Li">Jiu-Xiang Li</name>
</author>
<author><name sortKey="Lu, Jia Hai" sort="Lu, Jia Hai" uniqKey="Lu J" first="Jia-Hai" last="Lu">Jia-Hai Lu</name>
</author>
<author><name sortKey="Wan, Zhuo Yue" sort="Wan, Zhuo Yue" uniqKey="Wan Z" first="Zhuo-Yue" last="Wan">Zhuo-Yue Wan</name>
</author>
<author><name sortKey="Zheng, Huan Yin" sort="Zheng, Huan Yin" uniqKey="Zheng H" first="Huan-Yin" last="Zheng">Huan-Yin Zheng</name>
</author>
<author><name sortKey="Yan, Xin Ge" sort="Yan, Xin Ge" uniqKey="Yan X" first="Xin-Ge" last="Yan">Xin-Ge Yan</name>
</author>
<author><name sortKey="Meng, Min Jie" sort="Meng, Min Jie" uniqKey="Meng M" first="Min-Jie" last="Meng">Min-Jie Meng</name>
</author>
<author><name sortKey="Fan, Jiang Lin" sort="Fan, Jiang Lin" uniqKey="Fan J" first="Jiang-Lin" last="Fan">Jiang-Lin Fan</name>
</author>
</analytic>
<series><title level="j">Immunology letters</title>
<idno type="ISSN">0165-2478</idno>
<imprint><date when="2004" type="published">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antibodies, Viral (blood)</term>
<term>Antibodies, Viral (immunology)</term>
<term>Antibody Specificity</term>
<term>Antigens, Viral (immunology)</term>
<term>Immune Sera (immunology)</term>
<term>Immunoglobulin G (blood)</term>
<term>Immunoglobulin G (immunology)</term>
<term>Kinetics</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Neutralization Tests</term>
<term>SARS Virus (immunology)</term>
<term>Severe Acute Respiratory Syndrome (immunology)</term>
<term>Severe Acute Respiratory Syndrome (virology)</term>
<term>Vaccines, Inactivated (immunology)</term>
<term>Viral Vaccines (immunology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term>
<term>Immunoglobulin G</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term>
<term>Antigens, Viral</term>
<term>Immune Sera</term>
<term>Immunoglobulin G</term>
<term>Vaccines, Inactivated</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Antibody Specificity</term>
<term>Kinetics</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Neutralization Tests</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is a serious infectious threat to public health. To create a novel trial vaccine and evaluate its potency, we attempted to generate a SARS inactivated vaccine using SARS coronavirus (SARS-CoV) strain F69 treated with formaldehyde and mixed with Al(OH)3. Three doses of the vaccine were used to challenge three groups of BALB/c mice. We found that the mice exhibited specific IgM on day 4 and IgG on day 8. The peak titers of IgG were at day 47 in low-dose group (1:19,200) and high-dose group (1:38,400) whereas in middle-dose group (1:19,200), the peak was at day 40. On day 63, the IgG levels reached a plateau. Neutralization assay demonstrated that the antisera could protect Vero-E6 cells from SARS-CoV's infection. Analysis of the antibody specificity revealed that the mouse antisera contained a mixture of antibodies specifically against the structure proteins of SARS-CoV. Furthermore, the mouse antisera conferred higher amount of antibodies against protein N, polypeptide S4 and S2 than those of proteins M and 3CL. These findings suggest that the inactivated SARS-CoV could preserve its antigenicity and the inactivated vaccine can stimulate mice to produce high levels of antibodies with neutralization activity. Results also suggest that polypeptides originating from protein N or S might be a potential target for the generation of a recombinant SARS vaccine.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15388253</PMID>
<DateCompleted><Year>2005</Year>
<Month>04</Month>
<Day>20</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-2478</ISSN>
<JournalIssue CitedMedium="Print"><Volume>95</Volume>
<Issue>2</Issue>
<PubDate><Year>2004</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Immunology letters</Title>
<ISOAbbreviation>Immunol. Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Immunogenicity of SARS inactivated vaccine in BALB/c mice.</ArticleTitle>
<Pagination><MedlinePgn>139-43</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Severe acute respiratory syndrome (SARS) is a serious infectious threat to public health. To create a novel trial vaccine and evaluate its potency, we attempted to generate a SARS inactivated vaccine using SARS coronavirus (SARS-CoV) strain F69 treated with formaldehyde and mixed with Al(OH)3. Three doses of the vaccine were used to challenge three groups of BALB/c mice. We found that the mice exhibited specific IgM on day 4 and IgG on day 8. The peak titers of IgG were at day 47 in low-dose group (1:19,200) and high-dose group (1:38,400) whereas in middle-dose group (1:19,200), the peak was at day 40. On day 63, the IgG levels reached a plateau. Neutralization assay demonstrated that the antisera could protect Vero-E6 cells from SARS-CoV's infection. Analysis of the antibody specificity revealed that the mouse antisera contained a mixture of antibodies specifically against the structure proteins of SARS-CoV. Furthermore, the mouse antisera conferred higher amount of antibodies against protein N, polypeptide S4 and S2 than those of proteins M and 3CL. These findings suggest that the inactivated SARS-CoV could preserve its antigenicity and the inactivated vaccine can stimulate mice to produce high levels of antibodies with neutralization activity. Results also suggest that polypeptides originating from protein N or S might be a potential target for the generation of a recombinant SARS vaccine.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xiong</LastName>
<ForeName>Sheng</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Biomedical Research & Development Center, Floor 5, Building of Biology, Jinan University, Guangzhou 510630, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Yi-Fei</ForeName>
<Initials>YF</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zhang</LastName>
<ForeName>Mei-Ying</ForeName>
<Initials>MY</Initials>
</Author>
<Author ValidYN="Y"><LastName>Liu</LastName>
<ForeName>Xin-Jian</ForeName>
<Initials>XJ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zhang</LastName>
<ForeName>Chuan-Hai</ForeName>
<Initials>CH</Initials>
</Author>
<Author ValidYN="Y"><LastName>Liu</LastName>
<ForeName>Shi-Sheng</ForeName>
<Initials>SS</Initials>
</Author>
<Author ValidYN="Y"><LastName>Qian</LastName>
<ForeName>Chui-Wen</ForeName>
<Initials>CW</Initials>
</Author>
<Author ValidYN="Y"><LastName>Li</LastName>
<ForeName>Jiu-Xiang</ForeName>
<Initials>JX</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lu</LastName>
<ForeName>Jia-Hai</ForeName>
<Initials>JH</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wan</LastName>
<ForeName>Zhuo-Yue</ForeName>
<Initials>ZY</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zheng</LastName>
<ForeName>Huan-Yin</ForeName>
<Initials>HY</Initials>
</Author>
<Author ValidYN="Y"><LastName>Yan</LastName>
<ForeName>Xin-Ge</ForeName>
<Initials>XG</Initials>
</Author>
<Author ValidYN="Y"><LastName>Meng</LastName>
<ForeName>Min-Jie</ForeName>
<Initials>MJ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Fan</LastName>
<ForeName>Jiang-lin</ForeName>
<Initials>JL</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Immunol Lett</MedlineTA>
<NlmUniqueID>7910006</NlmUniqueID>
<ISSNLinking>0165-2478</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007106">Immune Sera</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000918" MajorTopicYN="N">Antibody Specificity</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007106" MajorTopicYN="N">Immune Sera</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year>
<Month>05</Month>
<Day>31</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2004</Year>
<Month>06</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2004</Year>
<Month>06</Month>
<Day>29</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2004</Year>
<Month>9</Month>
<Day>25</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2005</Year>
<Month>4</Month>
<Day>21</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2004</Year>
<Month>9</Month>
<Day>25</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">15388253</ArticleId>
<ArticleId IdType="doi">10.1016/j.imlet.2004.06.014</ArticleId>
<ArticleId IdType="pii">S0165-2478(04)00174-9</ArticleId>
<ArticleId IdType="pmc">PMC7112924</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Avian Pathol. 2003 Dec;32(6):567-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14676007</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2004 Mar 12;303(5664):1666-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14752165</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol Methods. 2003 Dec;283(1-2):45-57</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14659898</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>New Microbiol. 2003 Apr;26(2):151-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12737196</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2003 Nov 7;21(31):4519-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14575762</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Can J Vet Res. 2002 Oct;66(4):278-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12418784</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 May;78(9):4638-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15078946</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virus Res. 2002 Mar 20;84(1-2):101-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11900843</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 Apr;78(7):3572-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15016880</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Immunol Lett. 2004 Apr 15;92(3):237-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15081618</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15096611</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15024391</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 1992;10(4):214-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1348595</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2536-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14983044</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1977-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12671062</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2001 Sep 14;19(32):4635-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11535311</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B45 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002B45 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:15388253 |texte= Immunogenicity of SARS inactivated vaccine in BALB/c mice. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:15388253" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
This area was generated with Dilib version V0.6.33. |